# Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

> **NCT03359239** · PHASE1 · COMPLETED · sponsor: **Matthew Galsky** · enrollment: 10 (actual)

## Conditions studied

- Urothelial/Bladder Cancer, Nos

## Interventions

- **DRUG:** Atezolizumab
- **BIOLOGICAL:** PGV001
- **DRUG:** Poly ICLC
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03359239
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-08
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359239, "Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03359239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*